35 Cellular Diseases: A Comprehensive Guide to Causes, Symptoms, Diagnosis, and Treatment

Cellular pathology is a fundamental branch of biomedical science that examines how abnormalities in cellular structure, metabolism, signaling, and function contribute to human disease. From inherited mitochondrial disorders and lysosomal storage diseases to DNA repair defects and malignant transformation, cellular dysfunction provides a framework for understanding many of the most important conditions in modern medicine.

A comprehensive understanding of the 35 cellular diseases discussed in this article requires more than memorizing disease names. It involves identifying the affected cellular component, understanding the underlying molecular mechanism, recognizing characteristic clinical manifestations, and explaining how laboratory testing and modern therapeutic strategies can help manage each condition.

This article provides a structured, educational overview of 35 diseases associated with cellular dysfunction. It covers major organelles, including mitochondria, peroxisomes, lysosomes, the endoplasmic reticulum, and the nucleus, as well as disorders involving cell membranes, DNA repair, cell-cycle regulation, and cancer biology.

The content is intended for students, healthcare professionals, biomedical researchers, and readers seeking a deeper understanding of cellular pathology. It is an educational resource, not a substitute for individualized medical assessment.

1. What Are Cellular Diseases?

Cellular diseases are conditions in which normal cellular processes are disrupted by genetic variants, metabolic abnormalities, environmental exposures, infections, immune reactions, or acquired changes in cell regulation. The term describes a broad category rather than a single diagnostic classification.

A healthy cell depends on the coordinated activity of several structures:

• Mitochondria produce most of the ATP required for cellular activity through oxidative phosphorylation.

• Lysosomes digest and recycle macromolecules, damaged organelles, and cellular waste.

• Peroxisomes participate in fatty-acid metabolism and the detoxification of reactive oxygen species.

• The endoplasmic reticulum (ER) synthesizes and folds proteins and produces many lipids.

• The nucleus stores genetic information and regulates gene expression, DNA replication, and repair.

• The plasma membrane controls transport, cell signaling, and interactions with the extracellular environment.

• Cell-cycle regulatory systems coordinate cell growth, DNA replication, and division.

When one of these systems fails, the consequences may range from a localized cellular defect to a multisystem disorder. For example, mitochondrial dysfunction can impair energy-demanding tissues such as the brain, skeletal muscles, and heart. Lysosomal enzyme deficiencies may cause progressive accumulation of undegraded substances, while defects in DNA repair can increase chromosome instability and cancer susceptibility.

NCBI Bookshelf

+2

How Are Cellular Diseases Classified?

For clinical and educational purposes, cellular diseases can be grouped into seven major categories:

1. Mitochondrial disorders.

2. Peroxisomal disorders.

3. Lysosomal storage diseases.

4. Disorders of protein folding and intracellular transport.

5. Plasma-membrane and ion-channel disorders.

6. Nuclear and DNA-repair disorders.

7. Cell-cycle abnormalities and cancers.

These categories overlap. A genetic defect may affect several organelles, and a disease may involve both a primary molecular defect and secondary changes in other cellular pathways.

2. Thirty-Five Cellular Diseases Explained

Category I: Mitochondrial Diseases

Mitochondrial diseases result from abnormalities in mitochondrial structure, function, maintenance, or energy production. Pathogenic variants may occur in mitochondrial DNA or nuclear genes encoding proteins required for mitochondrial function.

Because mitochondria are essential for ATP production, tissues with high energy requirements are often especially vulnerable. Neurological, muscular, cardiac, auditory, and visual manifestations are common, although the presentation varies considerably between disorders.

NCBI Bookshelf

+1

1. Leigh Syndrome

Primary cellular defect: Impaired mitochondrial energy metabolism.

Leigh syndrome is a progressive neurological disorder associated with dysfunction of mitochondrial energy production. Depending on the genetic cause, defects may affect the respiratory chain, pyruvate metabolism, or other pathways involved in generating cellular energy.

The disease often begins in infancy or early childhood, although later presentations occur. Clinical manifestations can include developmental regression, hypotonia, movement abnormalities, seizures, swallowing difficulties, and abnormalities affecting the brainstem or basal ganglia.

Diagnosis may involve neurological assessment, brain magnetic resonance imaging (MRI), metabolic investigations, and molecular genetic testing. MRI can reveal characteristic abnormalities in deep brain structures, although findings depend on disease stage and cause.

Management is individualized and may include nutritional support, rehabilitation, seizure management, respiratory support, and treatment of specific metabolic defects when targeted interventions are available. Prognosis varies by genotype and clinical severity.

NCBI Bookshelf

+1

2. MELAS Syndrome

Full name: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.

MELAS is a multisystem mitochondrial disorder that affects energy-dependent tissues, particularly the brain and skeletal muscles. Many cases are associated with pathogenic mitochondrial DNA variants, including variants affecting mitochondrial protein synthesis.

Symptoms can include recurrent headaches, seizures, muscle weakness, exercise intolerance, hearing impairment, short stature, and episodes resembling strokes. Unlike typical vascular strokes, MELAS-associated stroke-like lesions do not necessarily follow conventional arterial territories.

Elevated blood or cerebrospinal fluid lactate may support the diagnosis, but lactate is not specific to MELAS and may be normal in some affected individuals. Brain MRI and molecular genetic testing help establish the diagnosis.

Treatment focuses on managing neurological complications, seizures, hearing loss, diabetes when present, and other systemic manifestations. Specialist-directed metabolic management is important because the effectiveness of individual interventions varies and evidence for some treatments remains limited.

NCBI Bookshelf

+1

3. MERRF Syndrome

Full name: Myoclonic epilepsy with ragged-red fibers.

MERRF is a mitochondrial disorder characterized by myoclonus, epilepsy, muscle dysfunction, and sometimes cerebellar ataxia. It is commonly associated with mitochondrial DNA variants affecting mitochondrial transfer RNA.

The cellular mechanism involves impaired mitochondrial protein synthesis and respiratory-chain function. As a result, muscle fibers may develop abnormal mitochondrial accumulation, producing the characteristic ragged-red appearance on specialized muscle staining.

Additional manifestations can include hearing loss, peripheral neuropathy, exercise intolerance, and cognitive difficulties. The severity and age of onset differ among affected individuals.

Diagnosis combines clinical evaluation with molecular genetic testing. Muscle biopsy may provide supporting evidence in selected cases but is not always necessary. Management generally includes treatment of seizures and other symptoms, rehabilitation, and monitoring of affected organ systems.

4. Leber Hereditary Optic Neuropathy (LHON)

LHON is an inherited mitochondrial disorder that primarily affects retinal ganglion cells, the neurons that transmit visual information from the retina to the brain.

Pathogenic mitochondrial DNA variants impair mitochondrial energy production and can make these cells vulnerable to metabolic stress. The characteristic presentation is painless, subacute loss of central vision, often beginning in one eye and subsequently affecting the other.

Color-vision abnormalities and central visual-field defects may accompany the loss of visual acuity. Although LHON is more commonly symptomatic in males, inheritance and disease expression are more complex than a simple sex-linked pattern.

Diagnosis involves ophthalmological examination, visual-field testing, optical coherence tomography when appropriate, and molecular testing for pathogenic mitochondrial DNA variants. Management may include genetic counseling, visual rehabilitation, avoidance of smoking and excessive alcohol consumption, and specialist consideration of approved treatments where available.

NCBI Bookshelf

+1

5. Kearns–Sayre Syndrome

Kearns–Sayre syndrome is a mitochondrial disorder typically associated with large-scale deletions in mitochondrial DNA. It can affect several organs because mitochondrial dysfunction interferes with energy production in multiple tissues.

Characteristic findings include progressive external ophthalmoplegia, pigmentary retinal abnormalities, and cardiac conduction defects. Other manifestations may involve hearing, endocrine function, skeletal muscles, and the nervous system.

The disease is particularly important clinically because cardiac conduction abnormalities can become life-threatening even when neurological symptoms appear relatively stable.

Evaluation may include ophthalmological examination, electrocardiography, cardiac monitoring, endocrine investigations, and genetic testing. Management requires multidisciplinary care and may include a pacemaker for clinically significant conduction disease, together with treatment of associated complications.

NCBI Bookshelf

+1

Category II: Peroxisomal Diseases

Peroxisomes are membrane-bound organelles involved in the oxidation of specific fatty acids, the metabolism of certain lipids, and the control of reactive oxygen species. Their enzymes include oxidases and catalase.

Peroxisomal disorders may arise when peroxisomes cannot assemble correctly or when an individual enzyme or transporter is defective. These abnormalities can affect the nervous system, liver, adrenal glands, vision, hearing, and other organs.

NCBI Bookshelf

+1

6. Zellweger Spectrum Disorder

Zellweger spectrum disorder is a group of inherited conditions caused by defects in peroxisome biogenesis, commonly involving genes in the PEX family.

When peroxisomes fail to assemble or function properly, the cell cannot adequately perform several metabolic reactions. Very-long-chain fatty acids and other abnormal metabolites may accumulate, while the synthesis or metabolism of important lipids becomes disrupted.

Severe forms can present in newborns with hypotonia, feeding difficulties, seizures, liver dysfunction, hearing loss, visual impairment, and structural abnormalities. Milder forms may become apparent later in childhood with developmental delay or sensory deficits.

Diagnosis typically involves biochemical testing, including measurement of very-long-chain fatty acids, followed by molecular genetic analysis. Management is primarily supportive and tailored to neurological, nutritional, hepatic, auditory, and visual complications. Severity varies widely across the spectrum.

NCBI Bookshelf

+1

7. X-Linked Adrenoleukodystrophy (X-ALD)

X-linked adrenoleukodystrophy is caused by pathogenic variants in the ABCD1 gene, which encodes a transporter involved in moving very-long-chain fatty-acid substrates into peroxisomes.

The transport defect interferes with fatty-acid metabolism and leads to abnormal accumulation of very-long-chain fatty acids in tissues. Important clinical manifestations include progressive inflammatory damage to cerebral white matter, adrenal insufficiency, and a slowly progressive spinal-cord and peripheral-nerve disorder in some adults.

The clinical presentation is variable, even among people carrying the same pathogenic variant. Biochemical testing and genetic analysis are used to establish the diagnosis. MRI surveillance is particularly important in at-risk individuals because early cerebral disease may be treatable before extensive neurological damage develops.

Management may include adrenal hormone replacement, neurological monitoring, supportive care, and assessment for specialist interventions such as hematopoietic stem-cell transplantation or gene therapy in appropriately selected patients with cerebral disease.

NCBI Bookshelf

8. Adult Refsum Disease

Adult Refsum disease is an inherited metabolic disorder in which phytanic acid cannot be broken down normally through peroxisomal alpha-oxidation.

The resulting accumulation of phytanic acid can affect peripheral nerves, the retina, the auditory system, and the cerebellum. Typical manifestations include retinitis pigmentosa, night blindness, peripheral neuropathy, hearing loss, and impaired coordination. Some patients also develop cardiac abnormalities.

Diagnosis relies on biochemical measurement of phytanic acid, interpreted alongside clinical findings and molecular testing where indicated.

Management commonly includes a specialist-supervised diet restricting phytanic-acid intake, avoidance of prolonged fasting during acute illness, and treatment of associated complications. Dietary management can lower phytanic-acid levels, but established neurological damage may not be fully reversible.

9. Acyl-CoA Oxidase Deficiency

Acyl-CoA oxidase deficiency is a rare inherited peroxisomal disorder associated with pathogenic variants in ACOX1, a gene encoding an enzyme required for the initial oxidation step in peroxisomal beta-oxidation of certain fatty acids.

The enzyme deficiency impairs fatty-acid metabolism and can cause accumulation of very-long-chain fatty acids. Neurological manifestations may include developmental delay, hypotonia, seizures, abnormal muscle tone, and progressive white-matter disease.

Clinical severity varies. Diagnosis involves specialized biochemical investigations and molecular genetic testing.

There is no universally effective curative treatment for established disease. Care generally focuses on neurological and nutritional support, management of seizures and movement disorders, and monitoring for disease progression. Early recognition is valuable for accurate counseling and coordinated care.

10. D-Bifunctional Protein Deficiency

D-bifunctional protein deficiency is another inherited peroxisomal beta-oxidation disorder, most commonly associated with pathogenic variants in HSD17B4.

The affected protein participates in multiple steps of fatty-acid breakdown. Dysfunction can therefore interfere with the metabolism of very-long-chain fatty acids and other important substrates.

Severe cases may present in infancy with hypotonia, seizures, developmental impairment, sensory deficits, and progressive neurological disease. The phenotype depends partly on residual enzyme function.

Diagnosis is based on biochemical evidence of impaired peroxisomal metabolism and molecular testing. Treatment is supportive and may involve feeding assistance, seizure control, physiotherapy, hearing and vision services, and management of other organ complications.

Category III: Lysosomal Storage Diseases

Lysosomes contain acid hydrolases that break down proteins, carbohydrates, lipids, and other cellular materials. Their normal function supports intracellular recycling and the removal of unwanted substances.

When a lysosomal enzyme, transporter, or related protein is deficient, substrates can accumulate inside cells. These disorders are collectively known as lysosomal storage diseases. They can affect the spleen, liver, bones, heart, kidneys, brain, and peripheral nervous system.

NCBI Bookshelf

+1

11. Gaucher Disease

Gaucher disease is caused by deficient activity of the lysosomal enzyme glucocerebrosidase, usually due to pathogenic variants in GBA1. The enzyme normally helps break down glucosylceramide.

When enzyme activity is insufficient, lipid substrates accumulate in macrophages, creating characteristic storage cells. The resulting disease may cause an enlarged liver and spleen, anemia, low platelet counts, bone pain, and skeletal complications. Some forms also cause progressive neurological disease.

Clinical severity ranges from relatively mild adult-onset disease to severe early-onset forms.

Diagnosis generally involves enzyme-activity testing and molecular genetic analysis. Treatment options for selected forms include enzyme replacement therapy and substrate reduction therapy, alongside management of hematological and skeletal complications. Neurological forms require specialized care because available therapies do not address every neurological manifestation.

NCBI Bookshelf

+1

12. Tay–Sachs Disease

Tay–Sachs disease is a lysosomal storage disorder caused by deficiency of beta-hexosaminidase A, most often due to pathogenic variants in HEXA.

This enzyme normally contributes to the degradation of GM2 ganglioside. Without adequate activity, GM2 accumulates in neurons, leading to progressive neurological dysfunction.

The classic infantile form can present with developmental regression, exaggerated startle responses, muscle weakness, seizures, and progressive loss of neurological function. Other, later-onset forms can have different clinical patterns.

Diagnosis uses enzyme assays and molecular testing. Management focuses on supportive neurological care, nutrition, respiratory health, seizure treatment, and family counseling. At present, established Tay–Sachs disease does not have a broadly available curative treatment.

13. Niemann–Pick Disease

Niemann–Pick disease is a name historically used for several distinct inherited lipid-storage disorders. Types A and B are associated with deficient acid sphingomyelinase activity, while type C involves defects in intracellular lipid trafficking.

These disorders differ in their molecular mechanisms and clinical presentations. Depending on the type, manifestations may include hepatosplenomegaly, lung disease, neurological regression, impaired coordination, swallowing difficulties, and abnormal eye movements.

Diagnosis requires subtype-specific biochemical testing and/or molecular analysis. It is important not to treat all Niemann–Pick disorders as a single disease, because prognosis and available treatments differ. Management may include supportive care and, for certain subtypes and jurisdictions, disease-specific therapy.

NCBI Bookshelf

14. Pompe Disease

Pompe disease results from deficient lysosomal acid alpha-glucosidase, an enzyme required to break down glycogen within lysosomes.

As glycogen accumulates, muscle cells become progressively impaired. The heart and skeletal muscles can be especially affected, although the degree of cardiac involvement depends on the age of onset and residual enzyme activity.

Infantile-onset disease may cause severe muscle weakness, feeding problems, respiratory compromise, and hypertrophic cardiomyopathy. Later-onset disease more commonly presents with progressive weakness of proximal muscles and respiratory insufficiency.

Diagnosis is based on enzyme testing and genetic analysis. Enzyme replacement therapy is an established disease-specific treatment for appropriate patients, with respiratory support, physiotherapy, nutritional care, and cardiac assessment as needed.

15. Fabry Disease

Fabry disease is an inherited lysosomal disorder caused by deficient alpha-galactosidase A activity, usually due to pathogenic variants in GLA.

The deficiency results in accumulation of globotriaosylceramide and related substrates in cells, including vascular endothelial cells, kidney cells, and cardiac tissue.

Symptoms may include burning pain in the hands and feet, reduced sweating, characteristic skin lesions called angiokeratomas, gastrointestinal symptoms, kidney dysfunction, cardiac disease, and increased risk of stroke.

Clinical expression is variable, including among females. Diagnosis involves enzyme testing, particularly in males, and molecular genetic analysis. Disease-specific options include enzyme replacement therapy and, for selected variants, pharmacological chaperone therapy. Renal, cardiac, neurological, and pain management remain important components of care.

NCBI Bookshelf

Category IV: Endoplasmic Reticulum, Protein Folding, and Intracellular Transport

The endoplasmic reticulum is responsible for synthesizing many proteins and lipids, folding newly synthesized proteins, and preparing proteins for transport to other cellular compartments. Proteins that fold incorrectly may be retained and degraded, while persistent accumulation of misfolded proteins can trigger cellular stress responses.

Defects in protein processing and intracellular transport can affect several organs, depending on which proteins and pathways are involved.

16. Cystic Fibrosis

Cystic fibrosis is an inherited disease caused by pathogenic variants in CFTR, the gene encoding a membrane protein that regulates chloride and bicarbonate transport.

Some CFTR variants cause the protein to fold incorrectly and be degraded before reaching the plasma membrane. Other variants impair channel opening, conductance, or protein production. The resulting ion-transport defect changes the composition of secretions, particularly in the lungs and digestive system.

Clinical manifestations include persistent respiratory infections, chronic airway inflammation, pancreatic insufficiency, poor weight gain, and elevated sweat chloride concentrations. Severity varies with the genotype and other biological factors.

Diagnosis commonly involves sweat chloride testing and molecular analysis. Treatment may include airway clearance, infection management, pancreatic enzyme replacement, nutritional support, and CFTR modulators for patients with eligible variants. The condition illustrates how a molecular defect in a single membrane protein can affect several organ systems.

17. Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency is an inherited disorder associated with pathogenic variants in SERPINA1. Certain abnormal forms of the alpha-1 antitrypsin protein misfold and accumulate within the endoplasmic reticulum of hepatocytes.

This creates two distinct disease mechanisms. Reduced circulating alpha-1 antitrypsin can leave lung tissue vulnerable to protease-mediated injury, while intracellular protein accumulation can cause liver damage.

Patients may develop emphysema, chronic respiratory symptoms, neonatal or adult liver disease, and, in some cases, cirrhosis or hepatocellular carcinoma.

Diagnosis may include serum alpha-1 antitrypsin concentration, protein phenotyping, and genetic testing. Management includes smoking avoidance, treatment of pulmonary disease, liver monitoring, and selected augmentation therapy for appropriate patients with lung disease. The condition demonstrates that defective protein folding can cause both a loss of normal function and toxic accumulation inside cells.

18. Charcot–Marie–Tooth Disease

Charcot–Marie–Tooth disease refers to a group of inherited peripheral neuropathies caused by abnormalities in genes required for peripheral nerve function.

Depending on the subtype, cellular defects may affect myelin production, axonal transport, cytoskeletal organization, mitochondrial function, or protein processing. Because peripheral nerves depend on long axons and specialized supporting cells, even relatively subtle defects can progressively impair nerve conduction.

Common manifestations include distal muscle weakness, foot deformities, reduced reflexes, sensory loss, and difficulty walking. The age of onset and rate of progression vary widely.

Diagnosis may involve neurological examination, nerve-conduction studies, genetic testing, and evaluation for alternative causes of neuropathy. Management generally includes physiotherapy, orthoses, occupational therapy, pain management, and orthopedic intervention when necessary.

19. Wilson Disease

Wilson disease is an inherited disorder of copper metabolism caused by pathogenic variants in ATP7B, which encodes a protein involved in intracellular copper transport.

The defect disrupts normal copper handling by hepatocytes, including biliary copper excretion. Copper can accumulate in the liver and subsequently affect the brain, cornea, kidneys, and other tissues.

Symptoms may include hepatitis, cirrhosis, tremor, dystonia, psychiatric changes, and movement abnormalities. Presentation ranges from asymptomatic biochemical abnormalities to serious hepatic or neurological disease.

Diagnostic assessment may include liver-function testing, ceruloplasmin measurement, urinary copper testing, slit-lamp examination for Kayser–Fleischer rings, and genetic analysis. Treatment commonly involves copper-chelating agents or zinc therapy under specialist supervision. Early treatment can substantially reduce the risk of progressive organ damage.

20. Hereditary Hemochromatosis

Hereditary hemochromatosis comprises inherited disorders that cause excessive iron absorption and progressive iron accumulation in tissues.

In the common HFE-related form, altered iron-regulatory signaling leads to increased intestinal iron absorption. Excess iron promotes oxidative stress and can damage hepatocytes, pancreatic cells, cardiomyocytes, and other tissues.

Clinical manifestations may include liver disease, diabetes, joint symptoms, skin pigmentation changes, hypogonadism, and cardiomyopathy. Many affected individuals have no obvious symptoms during early disease.

Diagnosis typically involves transferrin saturation, ferritin measurement, assessment of liver injury, and genetic testing when indicated. Therapeutic phlebotomy is standard treatment for many patients with iron overload. The cellular pathology involves iron-mediated oxidative damage rather than a primary structural defect in a single organelle.

Category V: Cell Membrane and Ion-Channel Disorders

The plasma membrane maintains the cell's internal environment and mediates transport, electrical signaling, receptor activity, and interactions with surrounding tissues. Its functions depend on lipids, membrane proteins, ion channels, and cytoskeletal attachments.

Abnormalities in these components can impair red blood cell integrity, muscle contraction, cardiac electrical activity, and nerve signaling.

21. Sickle Cell Disease

Sickle cell disease is an inherited hemoglobin disorder caused by pathogenic variants in HBB that produce abnormal hemoglobin S.

When deoxygenated, hemoglobin S can polymerize, changing the shape and mechanical properties of red blood cells. Repeated sickling damages the membrane, shortens red blood cell survival, and promotes vascular obstruction.

Consequences include chronic hemolytic anemia, painful vaso-occlusive episodes, acute chest syndrome, stroke, infection risk, and progressive organ injury.

Diagnosis generally relies on hemoglobin analysis, supported by molecular testing where appropriate. Management may include vaccination, infection prevention, hydroxyurea, transfusion strategies, pain management, and selected curative approaches such as hematopoietic stem-cell transplantation or gene-based therapies. The underlying defect originates in hemoglobin, but the resulting membrane damage and cellular deformation drive much of the disease.

22. Hereditary Spherocytosis

Hereditary spherocytosis is an inherited red blood cell membrane disorder commonly involving proteins such as spectrin, ankyrin, band 3, or protein 4.2.

These proteins help maintain the structural relationship between the red blood cell membrane and its internal cytoskeleton. When the supporting network is defective, membrane surface area is lost and cells become spherical rather than maintaining their normal flexible, biconcave shape.

Spherocytes are less deformable and may be trapped and destroyed in the spleen. Patients can develop hemolytic anemia, jaundice, splenomegaly, and pigment gallstones.

Diagnosis combines clinical history, blood counts, blood-film examination, reticulocyte assessment, and specialized membrane testing when needed. Management depends on severity and may include folate supplementation, monitoring for gallstones, transfusions in selected cases, or splenectomy after careful assessment of benefits and risks.

23. Brugada Syndrome

Brugada syndrome is an inherited cardiac electrical disorder associated in some cases with pathogenic variants affecting sodium-channel function, particularly in SCN5A.

Abnormal ion-channel activity alters cardiac electrical propagation and repolarization, creating susceptibility to dangerous ventricular arrhythmias. Not every patient has an identifiable pathogenic variant, and genetic findings must be interpreted alongside clinical evidence.

The syndrome may be asymptomatic or present with fainting, nocturnal agonal breathing, seizure-like episodes caused by arrhythmia, or sudden cardiac arrest.

Diagnosis involves electrocardiographic assessment, clinical history, exclusion of relevant mimics, and selected genetic testing. Management is risk-based and may include avoidance of fever-related triggers and certain medications, family evaluation, and an implantable cardioverter-defibrillator in appropriately selected high-risk patients.

24. Long QT Syndrome

Long QT syndrome is a group of disorders involving abnormal cardiac repolarization. Some forms are inherited and arise from pathogenic variants in genes encoding cardiac ion channels or related proteins.

The cellular defect prolongs the ventricular action potential and the QT interval on an electrocardiogram, increasing susceptibility to torsades de pointes and other potentially life-threatening arrhythmias.

Symptoms may include fainting, palpitations, seizure-like episodes, or cardiac arrest. Some affected individuals remain asymptomatic until exposed to a trigger such as exercise, emotional stress, or a QT-prolonging medication.

Diagnosis involves electrocardiography, clinical risk assessment, medication review, and genetic testing when appropriate. Management may include beta-blockers, trigger avoidance, family screening, and device therapy in selected cases.

25. Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disease caused by pathogenic variants in DMD, leading to absent or severely reduced dystrophin protein.

Dystrophin helps stabilize the muscle-cell membrane during contraction by connecting the internal cytoskeleton to a membrane-associated protein complex. Without adequate dystrophin, repeated contraction causes membrane injury, calcium dysregulation, inflammation, and progressive muscle-fiber degeneration.

Clinical manifestations include early childhood muscle weakness, difficulty rising from the floor, progressive walking impairment, and later respiratory and cardiac complications.

Diagnosis involves clinical evaluation, creatine kinase measurement, and genetic testing. Management may include corticosteroids, cardiac and respiratory surveillance, physiotherapy, orthopedic care, and mutation-specific or other disease-modifying treatments for eligible patients.

Category VI: Nuclear and DNA-Repair Disorders

The nucleus houses most of the cell's genetic material. Accurate DNA replication and repair are essential for normal development, cell survival, and the prevention of cancer.

DNA damage occurs naturally during cellular metabolism and can also result from radiation, chemicals, and other environmental exposures. Repair pathways recognize and correct different types of damage. Defects in these pathways can cause genomic instability, developmental abnormalities, premature aging phenotypes, or increased cancer susceptibility.

NCBI

+1

26. Hutchinson–Gilford Progeria Syndrome

Hutchinson–Gilford progeria syndrome is a rare genetic condition associated with pathogenic variants in LMNA, which encodes lamin A and lamin C, proteins that help maintain the structure and organization of the nuclear envelope.

Most classic cases result from abnormal processing of lamin A and production of progerin, an abnormal protein that disrupts nuclear architecture and contributes to cellular dysfunction.

Children with the condition may develop severe growth failure, characteristic skin and hair changes, joint stiffness, and premature cardiovascular disease. The most serious complications often involve progressive atherosclerotic disease.

Diagnosis is based on clinical findings and molecular genetic testing. Management includes multidisciplinary monitoring and treatment of cardiovascular, musculoskeletal, and nutritional complications. Disease-specific therapy may be available in some jurisdictions, but ongoing specialist care remains essential.

27. Fanconi Anemia

Fanconi anemia is an inherited disorder affecting DNA repair, particularly the pathway responsible for resolving DNA interstrand crosslinks.

When this repair pathway is defective, cells become unusually sensitive to certain forms of DNA damage and may accumulate chromosome abnormalities. Bone marrow stem cells are especially vulnerable, contributing to progressive bone marrow failure.

Clinical features can include short stature, abnormal skin pigmentation, skeletal differences, congenital anomalies, low blood-cell counts, and increased risks of myelodysplastic syndrome, leukemia, and solid tumors.

Diagnosis may involve chromosome-breakage testing using agents such as diepoxybutane or mitomycin C, followed by molecular genetic analysis. Management includes blood-count surveillance, cancer screening, specialist hematological care, and consideration of hematopoietic stem-cell transplantation for appropriate indications.

NCBI Bookshelf

+1

28. Ataxia-Telangiectasia

Ataxia-telangiectasia is an inherited disorder caused by pathogenic variants in ATM, a gene involved in sensing DNA double-strand breaks and coordinating cellular responses to DNA damage.

Defective ATM signaling compromises genome maintenance and affects several systems, including the nervous and immune systems. The condition typically presents with progressive cerebellar ataxia during childhood and may include telangiectasias, immunodeficiency, recurrent infections, and increased malignancy risk.

Cells may exhibit abnormal responses to ionizing radiation because DNA-damage signaling is impaired.

Diagnosis involves clinical assessment, immune evaluation when indicated, and molecular genetic testing. Management includes rehabilitation, treatment of infections and immune complications, respiratory care, and cancer surveillance. Medical imaging and radiation exposure should be considered carefully by the treating team when clinically relevant.

NCBI Bookshelf

+1

29. Xeroderma Pigmentosum

Xeroderma pigmentosum is a group of inherited disorders in which nucleotide excision repair or a related DNA-damage tolerance mechanism is impaired.

Under normal circumstances, these systems help cells cope with DNA damage caused by ultraviolet radiation. When the pathways are defective, UV-induced DNA lesions accumulate, increasing mutation rates and susceptibility to skin and ocular cancers.

Clinical findings may include severe sun sensitivity, freckling at an early age, pigmentary changes, eye abnormalities, and early development of skin malignancies. Some subtypes also involve neurological degeneration.

Diagnosis is based on clinical features and molecular testing, with specialized cellular assays used in selected circumstances. Rigorous UV protection, regular dermatological and ophthalmological surveillance, and prompt treatment of suspicious lesions are central to care.

NCBI

+1

30. Down Syndrome

Down syndrome is a chromosomal condition caused by extra genetic material from chromosome 21, most commonly through trisomy 21.

Unlike disorders caused by a single enzyme deficiency, Down syndrome affects cellular biology through altered gene dosage. Increased expression of genes on chromosome 21 influences developmental signaling, cell differentiation, immune function, and several organ systems.

Clinical features vary but may include characteristic physical traits, developmental delay, intellectual disability, congenital heart disease, hearing or vision problems, thyroid dysfunction, and increased risk of certain hematological disorders.

Diagnosis may occur prenatally or after birth using chromosome analysis or other validated genetic testing methods. Management is individualized and includes developmental support, screening for associated conditions, educational interventions, and treatment of specific medical complications. The clinical phenotype is variable, and no single feature defines every affected person.

Category VII: Cell-Cycle Dysregulation and Cancer

Cell division is controlled by a network of checkpoints, signaling proteins, tumor-suppressor genes, and DNA-repair mechanisms. These systems prevent damaged cells from multiplying and help eliminate cells that cannot be repaired.

Cancer develops when cells acquire changes that enable uncontrolled proliferation, survival despite cellular damage, invasion of surrounding tissues, and sometimes metastasis. Different cancers arise through different combinations of genetic, epigenetic, and environmental influences.

31. Lung Cancer

Lung cancer develops when abnormal cells in lung tissue acquire changes that disrupt normal proliferation, differentiation, and cell death.

At the cellular level, mutations can activate growth-promoting pathways or inactivate tumor-suppressor mechanisms. Depending on the subtype, relevant alterations may involve genes such as EGFR, KRAS, ALK, or TP53.

Symptoms can include persistent cough, coughing up blood, chest discomfort, breathlessness, and unexplained weight loss, although some cases are initially asymptomatic.

Diagnosis generally requires imaging and pathological examination of tissue or cytology specimens. Molecular profiling can identify alterations that guide targeted therapy in eligible patients. Treatment may include surgery, radiotherapy, chemotherapy, targeted drugs, immunotherapy, or combinations of these approaches.

Lung cancer illustrates how acquired changes in cell signaling and genomic regulation can transform a normal cell into a malignant one.

32. Colorectal Cancer

Colorectal cancer arises from malignant transformation of cells lining the colon or rectum. In many cases, cancer develops through a gradual accumulation of genetic and epigenetic abnormalities in epithelial cells.

Alterations affecting pathways involving APC, KRAS, TP53, and DNA mismatch repair can contribute to the transition from normal epithelium to adenoma and eventually invasive carcinoma. Not every tumor follows the same molecular sequence.

Symptoms may include changes in bowel habits, rectal bleeding, iron-deficiency anemia, abdominal discomfort, or unexplained weight loss. Some cancers are detected before symptoms develop through screening.

Diagnosis relies on colonoscopy and pathological assessment, with imaging and molecular tests used as indicated. Treatment depends on stage, tumor location, and molecular characteristics and may involve surgery, chemotherapy, radiotherapy, targeted treatment, or immunotherapy.

33. Leukemia

Leukemia is a group of malignancies originating from blood-forming cells in the bone marrow or related hematopoietic tissues.

Malignant cells acquire changes that disrupt normal differentiation, proliferation, or survival. The resulting abnormal cells can accumulate in the marrow and interfere with the production of healthy red blood cells, white blood cells, and platelets.

Clinical manifestations may include fatigue, infections, bruising, bleeding, fever, and bone pain. The symptoms and progression differ between acute and chronic leukemias and between myeloid and lymphoid forms.

Diagnosis typically includes a complete blood count, blood-film examination, bone marrow evaluation when indicated, immunophenotyping, and cytogenetic or molecular testing.

Treatment is disease-specific and may involve chemotherapy, targeted agents, immunotherapy, or hematopoietic stem-cell transplantation. Leukemia demonstrates how altered differentiation and proliferation can disrupt the normal organization of an entire cellular system.

34. Retinoblastoma

Retinoblastoma is a malignant tumor of the developing retina, usually occurring in young children. It is associated with inactivation of the RB1 tumor-suppressor gene.

The RB1 protein normally helps regulate progression through the cell cycle, particularly the transition from the G1 phase into DNA synthesis. When both functional copies are inactivated in a susceptible retinal cell, cell-cycle regulation can fail and malignant growth may occur.

The most recognizable clinical signs are leukocoria, or a white pupillary reflex, and sometimes strabismus. Early diagnosis is important because the disease can threaten both vision and life.

Diagnosis is usually based on specialist ophthalmological examination and appropriate imaging. Genetic counseling and testing are important when hereditary disease is suspected. Treatment may include focal therapies, chemotherapy, or surgery, depending on tumor extent and the potential to preserve vision.

Retinoblastoma is a classic example of cancer caused by disruption of a specific cell-cycle regulatory mechanism.

35. Breast Cancer

Breast cancer comprises several malignancies that arise from epithelial cells in breast tissue. Its development reflects interactions among genetic susceptibility, acquired molecular changes, hormonal signaling, and environmental or reproductive factors.

Some inherited pathogenic variants in BRCA1 and BRCA2 impair DNA repair through homologous recombination. Other tumors develop through acquired changes affecting hormone receptors, growth-factor signaling, cell-cycle control, or additional molecular pathways.

Clinical presentation may include a breast lump, skin changes, nipple abnormalities, or enlarged regional lymph nodes, although screening may identify tumors before symptoms appear.

Diagnosis generally involves clinical assessment, breast imaging, and tissue biopsy. Pathological testing determines tumor type and evaluates biomarkers such as estrogen receptor, progesterone receptor, and HER2 status. Treatment may include surgery, radiotherapy, endocrine therapy, chemotherapy, targeted treatment, or immunotherapy, depending on the tumor's characteristics and stage.

Breast cancer demonstrates that malignant transformation can result from several different cellular mechanisms, which is why molecular characterization is important for treatment selection.

3. How Are Cellular Diseases Diagnosed?

The diagnosis of a cellular disease requires a systematic approach that connects clinical findings with the underlying biological mechanism. A symptom alone rarely identifies a specific cellular defect.

Clinical assessment

The first step is to establish the patient's history, age at symptom onset, disease progression, affected organ systems, medication exposure, and family history. Inherited conditions may present in infancy, childhood, or adulthood, while acquired cellular abnormalities can develop at any age.

A detailed examination helps determine whether the disease is predominantly neurological, muscular, hematological, metabolic, hepatic, cardiac, or multisystemic.

Laboratory investigations

Laboratory testing depends on the suspected mechanism and may include:

• Complete blood count and blood-film examination.

• Liver and kidney function tests.

• Glucose, lactate, and other metabolic measurements.

• Enzyme-activity assays for suspected metabolic or lysosomal disorders.

• Measurement of specific metabolites, such as very-long-chain fatty acids or phytanic acid.

• Hemoglobin analysis for inherited hemoglobin disorders.

• Specialized biochemical testing for abnormal lipid or copper metabolism.

An abnormal laboratory result must be interpreted in clinical context. For example, elevated lactate is not specific to mitochondrial disease, and an abnormal enzyme result may require confirmation.

Genetic and molecular testing

Genetic testing can identify pathogenic variants responsible for many inherited cellular disorders. Depending on the clinical question, testing may involve a single gene, a targeted gene panel, chromosomal analysis, or broader sequencing approaches.

A genetic result does not automatically establish the cause of every symptom. Variant interpretation, inheritance patterns, biochemical findings, and clinical presentation must be considered together.

Imaging and pathological examination

Imaging can identify organ damage or characteristic disease patterns. Examples include brain MRI in selected mitochondrial and peroxisomal disorders, cardiac imaging for cardiomyopathy, and specialized ophthalmological examination for retinal disease.

Histopathology and cytology may reveal abnormal cellular morphology, storage material, tissue injury, or malignant transformation. Electron microscopy and specialized staining are useful in selected conditions, but they are not required for every cellular diagnosis.

4. Treatment Principles in Cellular Pathology

Treatment depends on whether the cellular defect is reversible, whether a targeted therapy exists, and how much irreversible tissue injury has occurred.

Treat the underlying mechanism when possible. Some disorders have therapies directed at a specific defect, including enzyme replacement for selected lysosomal diseases, copper-lowering treatment for Wilson disease, and CFTR modulators for eligible patients with cystic fibrosis.

Prevent secondary injury. Avoiding relevant triggers, correcting nutritional deficiencies, preventing infections, and reducing exposure to harmful substances can be important in selected disorders.

Monitor affected organs. Cellular diseases may progress silently before causing obvious symptoms. Surveillance can include cardiac assessment, neurological evaluation, blood counts, endocrine testing, eye examinations, and imaging, depending on the condition.

Use multidisciplinary care. Geneticists, pathologists, neurologists, hematologists, metabolic specialists, cardiologists, and other clinicians may be involved in diagnosis and management.

Consider genetic counseling. When a disease is inherited, counseling can help families understand inheritance, recurrence risk, testing options, and implications for relatives.

Not all cellular diseases are curable, and the effectiveness of treatments differs substantially. Early diagnosis can nevertheless improve the ability to prevent complications, identify treatment opportunities, and support affected individuals.

5. Cellular Pathology: Key Differences to Remember

6. Frequently Asked Questions About Cellular Diseases

What is the most common cause of cellular diseases?

There is no single most common cause across all cellular diseases. Some result from inherited genetic variants, others from acquired mutations, infections, toxins, metabolic disturbances, immune reactions, or environmental exposures. Cancer, for example, usually involves acquired cellular changes, while many classic lysosomal storage disorders are inherited.

Are cellular diseases always genetic?

No. Although many well-characterized cellular disorders are genetic, cellular dysfunction can also result from aging, infection, inflammation, ischemia, toxic exposure, and nutritional deficiencies. Genetic predisposition may interact with environmental factors.

Which cellular diseases affect mitochondria?

Examples include Leigh syndrome, MELAS, MERRF, Leber hereditary optic neuropathy, and Kearns–Sayre syndrome. These conditions differ in their genetic causes and clinical manifestations, but each involves mitochondrial dysfunction.

What is the difference between a lysosomal and a peroxisomal disease?

Lysosomes primarily digest and recycle cellular material. Lysosomal diseases commonly involve the accumulation of substances that cannot be degraded adequately. Peroxisomes participate in fatty-acid metabolism and other oxidative reactions; peroxisomal disorders can impair lipid metabolism and the handling of reactive metabolites.

Can cellular diseases be cured?

Some can be treated effectively, and selected conditions have disease-modifying or potentially curative interventions. Others require lifelong monitoring and supportive care. Treatment availability depends on the specific diagnosis, disease stage, genetic cause, and local access to specialist services.

Why is early diagnosis important?

Early diagnosis may identify opportunities to prevent organ damage, begin targeted treatment, arrange surveillance, and provide genetic counseling. In certain disorders, such as selected metabolic diseases and early cerebral X-linked adrenoleukodystrophy, timing can substantially influence treatment options.

Conclusion

Cellular pathology provides a unifying framework for understanding diseases that arise from abnormalities in organelles, proteins, membranes, DNA repair, metabolism, and cell-cycle regulation. The 35 conditions described here illustrate how defects at the molecular level can lead to diverse clinical outcomes, ranging from inherited metabolic disorders and progressive neurological disease to bone marrow failure and cancer.

The most effective way to study cellular diseases is to connect four elements: the affected cellular component, the molecular mechanism, the clinical manifestations, and the diagnostic or therapeutic implications. This approach is more useful than memorizing disease names alone and provides a foundation for further study in histology, biochemistry, genetics, pathology, and clinical medicine.

SEO Metadata

Primary SEO title

35 Cellular Diseases: Causes, Symptoms, Diagnosis, and Treatment

Target keywords

cellular diseases, cellular pathology, types of cellular diseases, mitochondrial diseases, peroxisomal disorders, lysosomal storage diseases, cell organelle disorders, genetic cellular disorders, DNA repair disorders, cell membrane diseases, causes of cellular dysfunction, cellular disease diagnosis, cellular disease treatment

Selected Scientific References

1. GeneReviews, Mitochondrial DNA-Associated Leigh Syndrome Spectrum. NCBI Bookshelf.

2. GeneReviews, MELAS. NCBI Bookshelf.

3. GeneReviews, Zellweger Spectrum Disorder. NCBI Bookshelf.

4. GeneReviews, X-Linked Adrenoleukodystrophy. NCBI Bookshelf.

5. GeneReviews, Gaucher Disease. NCBI Bookshelf.

6. GeneReviews, Fabry Disease. NCBI Bookshelf.

7. GeneReviews, Fanconi Anemia. NCBI Bookshelf.

8. National Library of Medicine, DNA Repair-Deficiency Disorders. Medical Subject Headings (MeSH).